Center-Authored Papers

Filters: Author is Ambinder, Richard F  [Clear All Filters]
Journal Article
Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, Jones RJ, Ambinder RF, Maris MB, Blume KG et al..  2008.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(11):1279-87. Abstract
Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell SM, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF et al..  2008.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(6):641-50. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA et al..  2017.  Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(5):608-638. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B et al..  2012.  Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(5):589-597. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R et al..  2015.  Hodgkin lymphoma, version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(5):554-86. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A et al..  2011.  Hodgkin lymphoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(9):1020-58.
Gantt S, Casper C, Ambinder RF.  2013.  Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention.. Current opinion in oncology. 25(5):495-502. Abstract
Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith DB et al..  2017.  Low immunosuppressive burden after HLA-matched related or unrelated BMT using post-transplantation cyclophosphamide.. Blood. Abstract
Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai H-L, Bolaños-Meade J, Morris LE, Crilley PA, O'Donnell PV, Rossiter N et al..  2010.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(4):482-9. Abstract
Bender Ignacio RA, Lee JY, Rudek MA, Dittmer DP, Ambinder RF, Krown SE.  2015.  A phase 1b/pharmacokinetic trial of PTC299, a novel post-transcriptional VEGF inhibitor, for AIDS-related Kaposi's sarcoma: AIDS Malignancy Consortium trial 059.. Journal of acquired immune deficiency syndromes (1999). Abstract
Lee JY, Dhakal I, Casper C, Noy A, Palefsky JM, Haigentz M, Krown SE, Ambinder RF, Mitsuyasu RT.  2016.  Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy.. Journal of cancer epidemiology. 2016:2138259. Abstract